Companies · Other Health Care

Great Basin Scientific, Inc.

West Valley City · Other Health Care

Diligence memoA one-page analyst read on Great Basin Scientific, Inc. — recommendation, valuation, rhythm, risks.
$124.3M
Total raised · real
6
Rounds
3.7×
Latest step-up
Top 4%
Sector rank · raised
Series C
Latest stage · inferred · Wed Jun 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Great Basin Scientific, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.49× the median modeled value of Series C Other Health Care companies in 2016–2018 (40 peers) — value vs value, same stage and era.
  • Within the normal band (149% of peer median) for its niche.
Dormant
  • Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Great Basin Scientific, Inc. is one of 5377 Other Health Care companies tracked from West Valley City. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2010-02-16 Raised $11M (real) Modeled valuation $223M (est)$11M$223MSeries A2010Series A · 2013-11-26 Raised $5.8M (real) Modeled valuation $117M (est)$5.8M$117MSeries A2013Series A · 2014-04-21 Raised $600K (real) Modeled valuation $12M (est)$600K$12MSeries A2014Series B · 2015-12-28 Raised $21M (real) Modeled valuation $454M (est)$21M$454MSeries B2015Series B · 2015-12-28 Raised $18M (real) Modeled valuation $408M (est)$18M$408MSeries B2015Series C · 2016-06-29 Raised $68M (real) Modeled valuation $1.6B (est)$68M$1.6BSeries C2016+$5.8M+$600K+$21M+$18M+$68MCumulative $124M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.0M · 2010
Series A extension$5.8M · 2013
Series A extension$600K · 2014
Series B$20.5M · 2015
Series B extension$18.4M · 2015
Series C$68.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$1.6B
Base estimate est.
$247.2M
Conservative case
$4.1B
Upside case
$453.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $222.8M · 2010-02-162010Series A · modeled $117.0M · 2013-11-26Series A · modeled $12.1M · 2014-04-21Series B · modeled $454.2M · 2015-12-28Series B · modeled $407.6M · 2015-12-28Series C · modeled $1.6B · 2016-06-292016
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
10.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$19.5M/yr
Capital velocity
16.4 yr
On record since
2010
First round
6
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 51× above median
This company$124.3M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.5× above median
This company$68.0M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 70× above median
This company$1.6B
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 98% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 40.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Specialty Networks, LLC · Series C Raised $94.5M · modeled $2.2B (est)New MMI Holdings, Inc. · Series C Raised $80.7M · modeled $1.8B (est)BioMatrix Holdings, L.L.C. · Series C Raised $80.0M · modeled $1.8B (est)Sea Hunter Holdings, LLC · Series C Raised $76.3M · modeled $1.7B (est)Bind Benefits, Inc. · Series C Raised $70.0M · modeled $1.6B (est)Endotronix Inc · Series C Raised $116.1M · modeled $1.6B (est)TransMedics, Inc. · Series C Raised $249.0M · modeled $1.5B (est)Landmark Health, LLC · Series C Raised $90.8M · modeled $1.4B (est)Rapid Micro Biosystems, Inc. · Series C Raised $134.6M · modeled $1.4B (est)Mdp Acm Holdings, Llc · Series C Raised $60.0M · modeled $1.4B (est)ACON BioMatrix Investors I, L.L.C. · Series C Raised $57.5M · modeled $1.3B (est)Great Basin Scientific, Inc. (this company) Raised $124.3M · modeled $1.6B (est)Great Basin Scientific, Inc.
CompanyStageRaised · realValue · estvs peer med.
Specialty Networks, LLCSeries C$94.5M$2.2B2.08×
New MMI Holdings, Inc.Series C$80.7M$1.8B1.77×
BioMatrix Holdings, L.L.C.Series C$80.0M$1.8B1.76×
Sea Hunter Holdings, LLCSeries C$76.3M$1.7B1.68×
Bind Benefits, Inc.Series C$70.0M$1.6B1.54×
Endotronix IncSeries C$116.1M$1.6B1.52×
Great Basin Scientific, Inc. this companySeries C$124.3M$1.6B1.49×
TransMedics, Inc.Series C$249.0M$1.5B1.40×
Landmark Health, LLCSeries C$90.8M$1.4B1.34×
Rapid Micro Biosystems, Inc.Series C$134.6M$1.4B1.32×
Mdp Acm Holdings, LlcSeries C$60.0M$1.4B1.32×
ACON BioMatrix Investors I, L.L.C.Series C$57.5M$1.3B1.26×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.0M2010-02-16$50.2M$222.8M90%
Series A$5.8M2013-11-26$26.4M$117.0M90%
Series A$600K2014-04-21$2.7M$12.1M90%
Series B$20.5M2015-12-28$113.9M$454.2M90%
Series B$18.4M2015-12-28$102.2M$407.6M90%
Series C$68.0M2016-06-29$453.3M$1.6B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.0M2010-02-16
    • First recorded raise — entered as Series A.
  2. Series A$5.8M2013-11-26
    • Raised again after 45 mo — slower than the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
  3. Series A$600K2014-04-21
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 9.7× smaller than the prior — bridge or down round.
  4. Series B$20.5M2015-12-28
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 34.2× larger than the prior — scaling up.
  5. Series B$18.4M2015-12-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  6. Series C$68.0M2016-06-29
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 3.7× larger than the prior — scaling up.
Intelligence
2017 ~Q4
Modeled next raise · ~15mo cadence
$204.0M
Modeled next size est.range $132.6M$326.4M
3.7×
Last step-up
$19.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kirk K. Calhoun1 other2015-12
Ronald K. Labrum1 other2015-12
Andrew D Olson2014-04
David D Spafford2014-04
David K. Spafford2015-12
David Spafford2010-02
Jeffrey D Rona2014-04
Jeffrey Rona2015-12
Laurence D Rea2014-04
Robert D. Jenison2014-04
Ryan Ashton2010-02
Sam K. Chawla2015-12
Sandra D. Nielsen2014-04
Stephen C. Aldous2010-02
Stephen D Aldous2014-04
Walter C. Hammond2015-12
Wesley C. Lindsey2015-12
Registry & provenance

Great Basin Scientific, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1512138
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Autonomic Technologies IncOther Health CareSeries C$125.6M$1.1Bsame sector · same stage
Well Dot, Inc.Other Health CareSeries C$122.8M$1.2Bsame sector · same stage
Avail Medsystems, Inc.Other Health CareSeries C$126.7M$2.2Bsame sector · same stage
Endogenex, Inc.Other Health CareSeries C$122.0M$576.1Msame sector · same stage
Hello Heart Inc.Other Health CareSeries C$127.0M$1.0Bsame sector · same stage
UANT Ventures, L.P.Other Health CareSeries C$120.4M$1.6Bsame sector · same stage
Precision Medicine Group Holdings, Inc.Other Health CareSeries C$119.8M$671.1Msame sector · same stage
BioDerm Holdings, LPOther Health CareSeries C$130.9M$1.0Bsame sector · same stage
Frequently asked
How much funding has Great Basin Scientific, Inc. raised?
Great Basin Scientific, Inc. has raised approximately $124.3M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Great Basin Scientific, Inc.'s estimated valuation?
Provath's modeled valuation for Great Basin Scientific, Inc. is approximately $1.6B (modeled range $247.2M–$4.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Great Basin Scientific, Inc. at?
Great Basin Scientific, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Jun 29.
What does Great Basin Scientific, Inc. do and where is it based?
Great Basin Scientific, Inc. operates in the Other Health Care sector, based in West Valley City.
Explore related

See where Great Basin Scientific, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Great Basin Scientific, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.